| Date Filed | Type | Description |
| 08/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis Topline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 — DURECT Corporation , a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment in its Phase 2b AHFIRM clinical trial investigating larsucosterol for the treatment of patients with severe alcohol-associated hepatitis , achieving its enrollment target of 300 patients. “We are excited to have reached this critical milestone and look forward to reporting topline data, anticipated in the fourth quarter of 2023,” said James E. Brown, D.V.M., President and Chief Executive Officer of DURECT. ..." |
|
| 05/16/2023 |
8-K
| Investor presentation |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/21/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/15/2023 |
4
| Bleichroeder LP (10% Owner) has filed a Form 4 on DURECT CORP|
Txns:
| Disposed of 3,498 shares
@ $0 |
|
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/08/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/23/2023 |
4
| Sussman Norman (Chief Medical Officer) has filed a Form 4 on DURECT CORP|
Txns:
| Granted 45,000 options to buy
@ $5.07, valued at
$228.2k
Granted 24,557 options to buy
@ $5.07, valued at
$124.5k
|
|
| 02/23/2023 |
4
| Papp Timothy M. (CFO) has filed a Form 4 on DURECT CORP|
Txns:
| Granted 60,000 options to buy
@ $5.07, valued at
$304.2k
Granted 12,377 options to buy
@ $5.07, valued at
$62.8k
|
|
| 02/23/2023 |
4
| Joice Judy R (Sr. VP Operations & Corp QA) has filed a Form 4 on DURECT CORP|
Txns:
| Granted 20,000 options to buy
@ $5.07, valued at
$101.4k
Granted 17,456 options to buy
@ $5.07, valued at
$88.5k
|
|
| 02/23/2023 |
4
| BROWN JAMES E (President & CEO) has filed a Form 4 on DURECT CORP|
Txns:
| Granted 200,000 options to buy
@ $5.07, valued at
$1M
Granted 50,665 options to buy
@ $5.07, valued at
$256.9k
|
|
| 02/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Form of Warrant (February 2023)",
"Form of Pre-Funded Warrant (February 2023)",
"Opinion of Orrick, Herrington & Sutcliffe LLP",
"Form of Securities Purchase Agreement",
"DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants CUPERTINO, Calif., February 3, 2023 / PRNewswire / — DURECT Corporation , a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of an aggregate of 1,700,000 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase 300,000 shares of common stock, and accompanying warrants to purchase up to 2,000,000 shares of common stock in a registered direct offering . The shares of common stock and ac..." |
|
| 02/03/2023 |
8-K
| Quarterly results |
| 12/20/2022 |
8-K
| Quarterly results |
| 11/28/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"DURECT Announces 1-for-10 Reverse Stock Split CUPERTINO, Calif., November 28, 2022/PRNewswire/ -- DURECT Corporation , a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT’s board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022. Beginning with the opening of trading on December 6, 2022, the Company's common stock will trade on a split-adjusted basis. At a Special Meeting of Stockholders held on November 22, 2022, DURECT stockholders voted to approve a proposal authorizing the board of directors of the Company to amend the Company's certificate of incorporation to effect a..." |
|
| 11/22/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/02/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/07/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/06/2022 |
8-K
| Quarterly results |
| 09/27/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 09/26/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|